

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		11604109	
	Filing Date		2006-11-24	
	First Named Inventor	Gerard M. Housey		
	Art Unit	1624		
	Examiner Name	Ward, Paul V.		
	Attorney Docket Number	00395/45		

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5858701		1999-01-12	White et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		11604109
Filing Date		2006-11-24
First Named Inventor	Gerard M. Housey	
Art Unit	1624	
Examiner Name	Ward, Paul V.	
Attorney Docket Number	00395/45	

1	LEVY, J.A. et al., "AIDS associated retroviruses (ARV) can productively infect other cells besides human T helper cells." Virology (1985), Vol. 147, pp. 441-448.	<input type="checkbox"/>
2	LOMBARDINO, J.G. et al., "Synthesis and antiinflammatory activity of some 3-carboxamides of 2-alkyl-4-hydroxy-2H-1,2-benzothiazine 1,1-dioxide." J. Med. Chem. (1971), Vol. 14, pp. 1171-1175.	<input type="checkbox"/>
3	LOMBARDINO, J.G. et al., "Antiinflammatory 3,4-dihydro-2-alkyl-3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxides." J. Med. Chem. (1971), Vol. 14, pp. 973-977.	<input type="checkbox"/>
4	LOMBARDINO, J.G. et al., "Preparation and antiinflammatory activity of some nonacidic trisubstituted imidazoles." J. Med. Chem. (1974), Vol. 17, pp. 1182-1188.	<input type="checkbox"/>
5	LOMBARDINO, J.G. et al., "New synthetic approaches to 3-carboxamides of 4-hydroxy-2H-1,2-benzothiazine 1,1-dioxide." J. Heterocyclic. Chem. (1976), Vol. 13, pp. 333-335.	<input type="checkbox"/>
6	LOMBARDINO, J.G., "Synthesis and antiinflammatory activity of metabolites of piroxicam." J. Med. Chem. (1981), Vol. 24, pp. 39-42.	<input type="checkbox"/>
7	LONG, S.D. et al., "Protease inhibitor antipain suppresses 12 O tetradecanoyl phorbol 13 acetate induction of plasminogen activator in transformable mouse embryo fibroblasts." Carcinogenesis (1981), Vol. 2, pp. 933-936.	<input type="checkbox"/>
8	LYERLY, H.K. et al., "Human T cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack." Proc. Natl. Acad. Sci. USA (1987), Vol. 84, pp. 4601-4605.	<input type="checkbox"/>
9	MACLEOD, C.L. et al., "EGF induces cell cycle arrest of A431 human epidermoid carcinoma cells." J. Cell. Physiol. (1986), Vol. 127, pp. 175-182.	<input type="checkbox"/>
10	MAIER, P. et al., "A two parameter flow cytometry protocol for the detection and characterization of the clastogenic, cytostatic and cytotoxic activities of chemicals." Mutat. Res. (1986), Vol. 164, pp. 369-379.	<input type="checkbox"/>
11	MATTHEWS, J.T. et al., "12-O-tetradecanoylphorbol-13-acetate stimulates phosphorylation of the 58,000-Mr form of polyomavirus middle T antigen in vivo: implications for a possible role of protein kinase C in middle T function." J. Virol. (1986), Vol. 58(2), pp. 239-246.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		11604109
Filing Date		2006-11-24
First Named Inventor	Gerard M. Housey	
Art Unit	1624	
Examiner Name	Ward, Paul V.	
Attorney Docket Number	00395/45	

12	MCDUGAL, J.S. et al., "Binding of HTLV III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule." Science (1986), Vol. 231(4736), pp. 382-385.	<input type="checkbox"/>
13	MCDUGAL, J.S. et al, "Binding of the human retrovirus HTLV III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry." J. Immunol. (1986), Vol. 137, pp. 2937-2944.	<input type="checkbox"/>
14	MEHRA, V. et al., "Efficient mapping of protein antigenic determinants." Proc. Natl. Acad. Sci. USA(1986), Vol. 83, pp. 7013-7017.	<input type="checkbox"/>
15	MODROW, S. et al., "Computer assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions." J. Virol. (1987), Vol. 61, pp. 570-578.	<input type="checkbox"/>
16	MOOLTEN, F.L., "Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy." Cancer Res. (1986), Vol. 46, pp. 5276-5281.	<input type="checkbox"/>
17	MORRISON, S.L. et al., "Chimeric human antibody molecules: mouse antigen binding domains with human constant region domains." Proc. Natl. Acad. Sci. USA (1984), Vol. 81, pp. 6851-6855.	<input type="checkbox"/>
18	MOUGNEAU, E. et al., "Biological activities of v myc and rearranged c myc oncogenes in rat fibroblast cells in culture." Proc. Natl. Acad. Sci. USA (1984), Vol. 81, pp. 5758-5762.	<input type="checkbox"/>
19	MURPHY, L.C. et al., "Differential effects of tamoxifen and analogs with nonbasic side chains on cell proliferation in vitro." Endocrinology (1984), Vol. 116, pp. 1071-1078.	<input type="checkbox"/>
20	MURRAY, H.W. et al., "Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome." N. Engl. J. Med. (1984), Vol. 310(14), pp. 883-889.	<input type="checkbox"/>
21	MUTSCHLER, E., Effects of Pharmaceutical Preparations (1975) pp. 231-235. (with translation)	<input type="checkbox"/>
22	NAKADATE, T. et al., "Inhibition of 12 O tetradecanoylphorbol 13 acetate induced tumor promotion and epidermal ornithine decarboxylase activity in mouse skin by palmitoylcarnitine." Cancer Res. (1986), Vol. 46, pp. 1589-1593.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	11604109
Filing Date	2006-11-24
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

23	NAKAMURA, G.R. et al., "Monoclonal Antibodies to the Extracellular Domain of HIV-1IIIB gp160 that Neutralize Infectivity, Block Binding to CD4, and React with Diverse Isolates." AIDS Res. and Human Retroviruses (1992), Vol. 8 (11), pp. 1875-1885.	<input type="checkbox"/>
24	NEPOM, G.T. et al., "Induction of immunity to a human tumor marker by in vivo administration of anti idiotypic antibodies in mice." Proc. Natl. Acad. Sci. USA (1984), Vol. 81, pp. 2864-2867.	<input type="checkbox"/>
25	NEUBERGER, M.S. et al., "Recombinant antibodies possessing novel effector functions." Nature (1984), Vol. 312 (5995), pp. 604-608.	<input type="checkbox"/>
26	NODA, M. et al., "Expression of functional sodium channels from cloned cDNA." Nature (1986), Vol. 322, pp. 826-828.	<input type="checkbox"/>
27	NOGUCHI, S. et al., "Expression of functional (Na ⁺ + K ⁺)-ATPase from cloned cDNAs." FEBS Lett. (1987), Vol. 225, pp. 27-32.	<input type="checkbox"/>
28	O'BRIAN, C.A. et al., "Current concepts of tumor promotion by phorbol esters and related compounds." In: New Insights into Cell and Membrane Transport Processes (1986) (Poste, G. and Crooke, S. T., eds., Plenum Publishing Co., New York, NY) pp. 261-274.	<input type="checkbox"/>
29	OI, V.T. et al., "Immunoglobulin-producing hybrid cell lines." In: Selected Methods in Cellular Immunology (Mishell, B. B. and Shiigi, S.M., eds., W.H. Freeman & Co., San Francisco, CA), (1980) pp. 351-372.	<input type="checkbox"/>
30	OGAWARA, H. et al., "A specific inhibitor for tyrosine protein kinase from Pseudomonas." J. Antibiot. (1986) (Tokyo), Vol.39, pp. 606-608.	<input type="checkbox"/>
31	PASTAN, et al. "Multidrug resistance." UCLA Symposia on Molecular & Cellular Biology Abstract A13, January 1986.	<input type="checkbox"/>
32	PEREZ, P. et al., "Specific targeting of cytotoxic T cells by anti T3 linked to anti target cell antibody." Nature(1985), Vol. 316(6026), pp. 354-356.	<input type="checkbox"/>
33	POPOVIC, M. et al., "Detection, isolation, and continuous production of cytopathic retroviruses (HTLV III) from patients with AIDS and pre AIDS." Science (1984), Vol. 224(4648), pp. 497-500.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		11604109
Filing Date		2006-11-24
First Named Inventor	Gerard M. Housey	
Art Unit		1624
Examiner Name	Ward, Paul V.	
Attorney Docket Number		00395/45

34	PUTNEY, S.D. et al., "HTLV III/LAV neutralizing antibodies to an E. coli produced fragment of the virus envelope." Science (1986), Vol. 234(4782), pp. 1392-1395.	<input type="checkbox"/>
35	RAHAINGOSON, F. et al., "On epot synthesis of furyl α -bromoketones from furyl ketones using the A-162 Br ₃ - resin/ CH ₃ NO ₂ system." Synth. Comm. (1992), Vol. 22, pp. 1923-1927.	<input type="checkbox"/>
36	RATNER, L. et al., "Complete nucleotide sequence of the AIDS virus, HTLV III." Nature (1985), Vol. 313(6000), pp. 277-284.	<input type="checkbox"/>
37	REDDEL, R.R. et al., "Differential sensitivity of human breast cancer cell lines to the growth inhibitory effects of tamoxifen." Cancer Res. (1985), Vol. 45, pp. 1525-1531.	<input type="checkbox"/>
38	REDDY, E.P. et al., "Complete nucleotide sequence and organization of the Moloney murine sarcoma virus genome." Science (1981), Vol. 214(4519), pp. 445-450.	<input type="checkbox"/>
39	REINECKE, M.G. et al., "An improved synthesis of thiophene-2,3-dicarboxylic acid by sequential carboxylation." Synthesis (April 1980), pp. 327-329.	<input type="checkbox"/>
40	RICHERT, N. et al., "Inhibition of the transformation specific kinase in ASV transformed cells by N alpha tosyl L lysyl chloromethyl ketone." Cell (1979), Vol. 18, pp. 369-374.	<input type="checkbox"/>
41	RIZZINO, A. et al., "Induction and modulation of anchorage independent growth by platelet derived growth factor, fibroblast growth factor, and transforming growth factor beta." Cancer Res. (1986), Vol. 46, pp. 2816-2820.	<input type="checkbox"/>
42	ROBERTS, A.B. et al., "Selective inhibition of the anchorage independent growth of myc transfected fibroblasts by retinoic acid." Nature (1985), Vol. 315(6016), pp. 237-239.	<input type="checkbox"/>
43	ROBEY, W.G. et al., "Prospect for prevention of human immunodeficiency virus infection: purified 120 kDa envelope glycoprotein induces neutralizing antibody." Proc. Natl. Acad. Sci. USA (1986), Vol. 83, pp. 7023-7027.	<input type="checkbox"/>
44	ROOK, A.H. et al., "Interleukin 2 enhances the depressed natural killer and cytomegalovirus specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome." J. Clin. Invest. (1983), Vol. 72, pp. 398-403.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		11604109
	Filing Date		2006-11-24
	First Named Inventor	Gerard M. Housey	
	Art Unit	1624	
	Examiner Name	Ward, Paul V.	
	Attorney Docket Number	00395/45	

45	ROY, S.K. et al., "High performance immunosorbent purification of recombinant leukocyte A interferon" J. Chromatogr. (1984), Vol. 303, pp. 225-228.	<input type="checkbox"/>
46	SANDSTROM, E.G. et al., "Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate." Lancet (1985), Vol. 1(8444), pp. 1480-1482.	<input type="checkbox"/>
47	SARNGADHARAN, M.G. et al., "Antibodies reactive with human T lymphotropic retroviruses (HTLV III) in the serum of patients with AIDS." Science (1984), Vol. 224(4648), pp. 506-508.	<input type="checkbox"/>
48	SCHAEFFER, W.I. et al., "Efficient detection of soft agar grown colonies using a tetrazolium salt." Cancer Lett. (1976), Vol. 1, pp. 259-262.	<input type="checkbox"/>
49	SCHLEICHER, R.L. et al., "Inhibition of hamster melanoma growth by estrogen." Cancer Res. (1987), Vol. 47, pp. 453-459.	<input type="checkbox"/>
50	SCHUPBACH, J. et al., "Serological analysis of a subgroup of human T lymphotropic retroviruses (HTLV III) associated with AIDS." Science (1984), Vol. 224(4648), pp. 503-505.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	11604109
Filing Date	2006-11-24
First Named Inventor	Gerard M. Housey
Art Unit	1624
Examiner Name	Ward, Paul V.
Attorney Docket Number	00395/45

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Lawrence P. Casson/	Date (YYYY-MM-DD)	2011-04-14
Name/Print	Lawrence P. Casson	Registration Number	46606

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.